Related Experiment Video
Updated: Aug 18, 2026

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
Published on: June 28, 2024
Reduced folate carrier gene is a risk factor for neural tube defects in a Chinese population
Lijun Pei1, Huiping Zhu, Aiguo Ren
1Institute of Reproductive and Child Health, Peking University Health Science Center, No. 38 Xueyuan Road, Haidian District, Beijing 100083, China. Peilj@healthychildren.org.cn
Insights
A specific gene variant (RFC1 GG genotype) increases the risk of neural tube defects (NTDs). This risk is significantly higher when mothers do not supplement with folic acid during pregnancy.
Area of Science:
- Genetics
- Maternal Health
- Developmental Biology
Background:
- Folic acid supplementation significantly reduces neural tube defects (NTDs).
- The precise mechanism of folic acid's protective effect is unknown.
- Folate transporter genes, like RFC1, are potential NTD risk factors.
Purpose of the Study:
- Investigate the association between RFC1 polymorphism (A80G) and NTD risk.
- Examine gene-environment interactions between infant RFC1 genotype and maternal folic acid use.
Main Methods:
- Population-based case-control study.
- Included 104 nuclear families with NTDs and 100 control families.
- Analyzed RFC1 A80G polymorphism in offspring and maternal folic acid intake.
Main Results:
- Infants with RFC1 GG genotype had a 2.56-fold increased NTD risk compared to AA genotype.
- Mothers not using folic acid had higher NTD risk for GG genotype offspring (OR 3.30).
- Combined GG genotype and no folic acid use elevated NTD risk significantly (OR 8.80) compared to supplemented mothers.
Conclusions:
- The RFC1 G allele is a significant genetic factor in folate transport.
- This RFC1 polymorphism may be a risk factor for NTDs in the Chinese population.
- Maternal folic acid supplementation mitigates the risk associated with the RFC1 GG genotype.
Background:
There is a considerable body of data demonstrating that periconceptional supplementation of folic acid can prevent a significant proportion of neural tube defects (NTDs). At present, the mechanism by which folic acid exerts its beneficial effect remains unknown. Folate transporter genes, including the reduced folate carrier gene (RFC1), have been proposed as NTD risk factors.
Methods:
The study population included 104 nuclear families with NTDs and 100 nonmalformed control families. We investigated the possible association between a common RFC1 polymorphism (A80G) and NTD risk among offspring, as well as potential gene-environment interactions between the infant RFC1 genotype and maternal periconceptional use of folic acid through a population-based case-control study.
Results:
We observed that the infants of the GG genotype were associated with a 2.56-fold increased risk of NTDs when compared to the AA genotype (odds ratio [OR], 2.56; 95% confidence interval [CI], 1.04-6.36) in our study population. Among mothers who did not utilize folic acid supplements, the risk for having a child with an NTD was 3.30 (95% CI, 1.15-9.65) for offspring with the GG genotype, compared to the reference (AA) genotype. Children who had the GG genotype and whose mothers did not take folic acid had an elevated risk for NTDs (OR, 8.80; 95% CI, 2.83-28.69), compared to offspring with the AA and GA genotypes whose mothers utilized folic acid supplements.
Conclusions:
Our findings suggest that the RFC1 G allele is likely to be an important genetic factor in determining folate transport and subsequently may be a risk factor for NTDs in this Chinese population.
More Related Videos
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
05:44Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1
Published on: May 17, 2024
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Neurulation
Teratogenicity
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life